口服地西他滨和cedazuridine联合venetoclax治疗老年或不适合强化疗的急性髓系白血病患者的2期研究
这项单中心2期研究评估了口服ASTX727(cedazuridine 100 mg与地西他滨35 mg)联合venetoclax在62例不适合强化疗的初治或复发难治急性髓系白血病患者中的疗效与安全性,初治组总缓解率为64%(30/47),复发难治组为46%(6/13),常见≥3级治疗中出现的不良事件为发热性中性粒细胞减少(18%),作者结论认为该全口服方案在多数老年或不适合患者中有效且安全,但需更大规模多中心研究证实。
要点
- ASTX727联合venetoclax的初治组总缓解率为64%(30/47,95%CI 49-77)。
- 复发难治组总缓解率为46%(6/13,95%CI 19-75)。
- 常见≥3级治疗中出现不良事件为发热性中性粒细胞减少(18%)。
核心结论
- ASTX727联合venetoclax是一种有效的全口服方案,在大多数老年或不适合的急性髓系白血病患者中安全。
- 作者指出该研究结果需在更大规模的多中心研究中证实。
研究设计与样本
- 单中心2期研究,纳入不适合强化化疗的初治急性髓系白血病患者(年龄≥75岁、ECOG体能状态2-3分或主要合并症)或复发难治急性髓系白血病患者。
- 复发难治队列要求年龄≥18岁且ECOG体能状态≤2分,既往治疗线数不限。
- 治疗方案为ASTX727(cedazuridine 100 mg和地西他滨35 mg)口服5天,venetoclax 400 mg口服21-28天,28天为一周期。
- 主要终点为ASTX727联合venetoclax的总缓解率,未完成第一周期且存活的患者不可评估缓解。
- 研究注册于ClinicalTrials.gov(NCT04746235),数据截止日期为2023年9月22日。
主要发现
- 2021年3月16日至2023年9月18日共纳入62例患者(初治49例,复发难治13例),中位年龄78岁(IQR 73-82)。
- 36例(58%)为男性;53例(85%)为白人,4例(6%)为黑人,2例(3%)为亚裔,3例(5%)为其他或未回答。
- 48例(77%)为欧洲白血病网2022不良风险,24例(39%)有 antecedent 骨髓增生异常综合征,12例(19%)既往低甲基化药物治疗失败,10例(16%)为治疗相关急性髓系白血病,11例(18%)有TP53突变。
- 中位随访时间为18.3个月(IQR 8.8-23.3)。
- 初治队列总缓解率为64%(30/47,95%CI 49-77),复发难治队列为46%(6/13,95%CI 19-75)。
关键数值与推荐
- 最常见的≥3级治疗中出现的不良事件为发热性中性粒细胞减少11/62(18%)、肺炎8例(13%)、呼吸衰竭5例(8%)、菌血症4例(6%)和脓毒症4例(6%)。
- 3例缓解期患者死亡(1例脓毒症、1例胃肠道出血、1例呼吸衰竭),可能与治疗相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出研究结果需在更大规模的多中心研究中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of decitabine that achieves equivalent area-under-curve exposure to intravenous decitabine. We performed a single centre phase 2 study to evaluate the efficacy and safety of ASTX727 plus venetoclax. METHODS: This study enrolled patients with newly diagnosed (frontline treatment group) acute myeloid leukaemia who were ineligible for intensive chemotherapy (aged ≥75 years, an Eastern Cooperative Oncology Group [ECOG] performance status of 2-3, or major comorbidities) or relapsed or refractory acute myeloid leukaemia. Being aged 18 years or older and having an ECOG performance status of 2 or less were requirements for the relapsed or refractory disease treatment cohort, without any limits in the number of previous lines of therapy. Treatment consisted of ASTX727 (cedazuridine 100 mg and decitabine 35 mg) orally for 5 days and venetoclax 400 mg orally for 21-28 days in 28-day cycles. The primary outcome was overall response rate of ASTX727 plus venetoclax. Living patients who have not completed cycle one were not evaluable for response. Safety was analysed in all patients who started treatment. This study was registered on ClinicalTrials.gov (NCT04746235) and is ongoing. The data cutoff date for this analysis was Sept 22, 2023. FINDINGS: Between March 16, 2021, and Sept 18, 2023, 62 patients were enrolled (49 frontline and 13 relapsed or refractory) with a median age of 78 years (IQR 73-82). 36 (58%) were male; 53 (85%) were White, 4 (6%) Black, 2 (3%) Asian and 3 (5%) other or did not answer. 48 (77%) of 62 patients were European LeukemiaNet 2022 adverse risk, 24 (39%) had antecedent myelodysplastic syndromes, 12 (19%) had previously failed a hypomethylating agent, ten (16%) had therapy-related acute myeloid leukaemia, and 11 (18%) had TP53 mutations. The median follow-up time was 18·3 months (IQR 8·8-23·3). The overall response rate was 30 (64%) of 47 patients (95% CI 49-77) in frontline cohort and six (46%) of 13 patients (19-75) in relapsed or refractory cohort. The most common grade 3 or worse treatment-emergent adverse events were febrile neutropenia in 11 (18%) of 62 patients, pneumonia in eight (13%), respiratory failure in five (8%), bacteraemia in four (6%), and sepsis in four (6%). Three deaths occurred in patients in remission (one sepsis, one gastrointestinal haemorrhage, and one respiratory failure) and were potentially treatment related. INTERPRETATION: ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies. FUNDING: MD Anderson Cancer Center Support Grant, Myelodysplastic Syndrome/Acute Myeloid Leukaemia Moon Shot, Leukemia SPORE, Taiho Oncology, and Astex Pharmaceuticals.
引用
- Bazinet A, Garcia-Manero G, Short N, et al. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024. PMID: 38452788. doi:10.1016/S2352-3026(24)00033-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。